BeiGene (SHSE:688235) Total Current Assets : ¥28,247 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is BeiGene Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BeiGene's total current assets for the quarter that ended in Mar. 2025 was ¥28,247 Mil.

BeiGene Total Current Assets Historical Data

The historical data trend for BeiGene's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Current Assets Chart

BeiGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

32,439.44

48,495.09

36,302.19

30,013.22

29,061.59

BeiGene Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															28,141.66	27,850.95	27,679.44	29,061.59	28,246.84

BeiGene Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BeiGene's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	19129.384	+	5162.788	+	3603.845	+	1165.574
	=	29,062

BeiGene's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	18242.218	+	5407.811	+	3585.939	+	1010.871
	=	28,247

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

BeiGene (SHSE:688235) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BeiGene's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	18242.218	-	16977.955	+	0.75 * 5199.481	+	0.5 * 3585.939
=	6,957

BeiGene Total Current Assets Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 06160:Hong Kong 49B:Germany 49B:Germany 49BA:Germany 49BA:Germany B1ME34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines